Maxcyte (MXCT) Cost of Revenue (2020 - 2026)

Maxcyte (MXCT) has 7 years of Cost of Revenue data on file, last reported at $1.6 million in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $1.6 million, up 4.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$247000.0 (up 96.98% YoY), and the FY2025 annual result was $6.2 million, down 12.37% from the prior year.
• Cost of Revenue climbed to $1.6 million in Q1 2026 per MXCT's latest filing, from -$9.2 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $7.2 million in Q4 2023 and troughed at -$13.1 million in Q4 2024.
• A 5-year average of $406982.4 and a median of $1.5 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue soared 474.44% in 2023, then plunged 281.85% in 2024.
• A 5-year view of Cost of Revenue shows it stood at -$8.2 million in 2022, then soared by 188.0% to $7.2 million in 2023, then sank by 281.85% to -$13.1 million in 2024, then advanced by 29.72% to -$9.2 million in 2025, then jumped by 117.06% to $1.6 million in 2026.
• Business Quant data shows MXCT's Cost of Revenue at $1.6 million in Q1 2026, -$9.2 million in Q4 2025, and $1.6 million in Q3 2025.